logo
CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.
William Blair's 45 th Annual Growth Stock Conference
Date: Tuesday, June 3, 2025
Time: 11:20 a.m. CT
Goldman Sachs' 46 th Annual Global Healthcare Conference
Date: Monday, June 9, 2025
Time: 3:20 p.m. ET
A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY ® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NIU Invest Completes Acquisition of Majority Stake in Critical Metals
NIU Invest Completes Acquisition of Majority Stake in Critical Metals

Business Wire

time23 minutes ago

  • Business Wire

NIU Invest Completes Acquisition of Majority Stake in Critical Metals

LONDON--(BUSINESS WIRE)--NIU Invest SE (NIU), headed by Austrian investor Cevdet Caner, completed its subscription for new Ordinary Shares of in Critical Metals PLC (Critical Metals) giving NIU an aggregate of 61,402,390 new Ordinary Shares, representing a majority 60.34% stake in the company. Critical Metals has a 70% stake in the Molulu Project, a cobalt and copper mining asset near Lubumbashi, in the Democratic Republic of Congo (DRC). The Molulu Project was previously mined by artisanal miners, and Critical Metals acquired the project in September 2022. Critical Metals plans to further develop and expand the Molulu Project's mining operations to realize the asset's full value. Caner stated, 'We are thrilled to complete this acquisition in the Democratic Republic of Congo and begin work on growing the operation and accelerating local development.' NIU is a leading Europe and US-based investment company focused on entrepreneurship and value creation, with the goal of becoming a fully integrated mining investor and operator with assets across North America, Latin America, Africa, and Europe. Austrian entrepreneur Cevdet Caner has invested in the mining and property sectors for over two decades. NIU plans to make further mining acquisitions in 2025, building a diverse portfolio of critical assets that drive long-term growth and align with the global demand for key inputs to advanced industries and cutting-edge technologies.

AVF and ErgoAV Merge to Expand Innovative AV Accessories and Mounting Solutions
AVF and ErgoAV Merge to Expand Innovative AV Accessories and Mounting Solutions

Business Wire

time23 minutes ago

  • Business Wire

AVF and ErgoAV Merge to Expand Innovative AV Accessories and Mounting Solutions

SHROPSHIRE, England--(BUSINESS WIRE)--Renowned British pioneer of AV mounting solutions AVF and fast-growing AV accessories and ergonomics brand ErgoAV today announced their merger, marking a momentous milestone and paving the way for continued growth and innovation for both companies. Consumers in global markets now benefit from an even broader choice of AV solutions and accessories, as both brands will bring in each other's products to their primary markets. AVF is an established industry leader in TV wall mounts, TV stands, and a wide range of AV furniture. Founded in 1977, the company has since become one of the largest AV mount and furniture brands in the UK. 'AVF is excited to join forces with ErgoAV, which will significantly expand our portfolio for both retail and commercial channels,' said Simon West, Managing Director of AVF. US-based ErgoAV has been building a name for itself since late 2022 with its innovative and ergonomically designed TV mounts, AV furniture, and smart office solutions—all by a team of known industry veterans with multi-decades of experience. ErgoAV is the US subsidiary of parent company Bestqi, one of the world's largest TV mount manufacturers, selling over five million units annually. The company had acquired AVF in June 2025, with the goal to enhance both brands' AV and office product offerings through combined expertise and leveraging Bestqi's R&D and manufacturing capabilities. 'The AVF, ErgoAV and Bestqi teams have collectively sold over 100 million TV mounts worldwide,' Henry Lyu, CEO of ErgoAV and Bestqi, shared. 'By merging ergonomics, smart home solutions, and thoughtful design, we aim to enhance every space with comfort, style, and next-generation innovation.' AVF and ErgoAV will retain their distinct brand identities while introducing each other's AV solutions, accessories, and furniture to the global market. This strategic synergy expands consumer choices, delivering creative and versatile options for modern homes and smart work spaces. About ErgoAV Led by a respected team of industry veterans, ErgoAV offers an innovative, ergonomic take on TV mounts, AV solutions, and accompanying accessories and furniture by seamlessly uniting form and function. Designed to enhance viewing and working experiences in any setup, whether home or office, ErgoAV's products optimize any space and provide endless possibilities with layout and viewing flexibility. For more information, please visit About AVF Founded in 1977, AVF has grown to become a leading AV mount brand in the UK and one of the world's leading suppliers of TV wall mounts and stylish TV stands. The company is known for its products' strength, durability, ease of installation, and design—all of which are continuously improved on and upgraded to align with market trends and user needs. For more information, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store